Medication Monitor

Generic Name (Trade Name—Company)
May 27, 2011


Treatment of Clostridium difficile-associated diarrhea


Treatment of adult patients with Clostridium difficile-associated diarrhea 

Fidaxomicin, formerly known as OPT-80, is primarily active against species of clostridia, including C. difficile, and works by inhibiting bacterial protein synthesis via transcription inhibition. A key advantage of fidaxomicin over currently available treatments is that this agent is thought to have less deleterious effects on intestinal microbiota, resulting in a lower rate of recurrent infections. The recommended dose is 200 mg twice daily for 10 days. When compared with vancomycin, fidaxomicin was found to be noninferior in terms of clinical response, but was associated with a better sustained response.